AFWERX, the Innovation Arm of the U.S. Air Force, Awards Phase II STTR Contract to Transcend Air
21.6.2022 14:03:00 EEST | Business Wire | Press release
Transcend Air announced today that it was awarded a Phase II Small Business Technology Transfer research and development contract from AFWERX, a Technology Directorate of the Air Force Research Laboratory. Transcend Air, in partnership with Auburn University, will further develop advanced flight control laws for high-speed flight with its Vy 400 vertical takeoff and landing aircraft (VTOL). “Specifically, the high speed flight is referred to as nap-of-the-earth (NOE) flight, which is a demanding regime where an aircraft stays low and follows the contours of terrain to remain undetected,” commented Peter Schmidt, COO of Transcend Air and Principal Investigator.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005201/en/
Advanced flight control laws developed in simulation (Photo: Business Wire)
Transcend Air is extending its work with Professor Imon Chakraborty and his Vehicle Systems, Dynamics, and Design Laboratory (VSDDL.com) and newly teaming with Professor Ehsan Taheri and his Aero-Astro Computational and Experimental Lab (ACE Lab). Control software will be demonstrated that enables the Vy 400 aircraft to automatically fly nap-of-the-earth in both simulation and real-world flight with 1/5th scale aircraft. The software reduces pilot workload and enables sustained flight in very close proximity to terrain at speeds two to three times faster than helicopters. This capability facilitates the mission of rescuing downed aircrews in one-quarter to one-eighth of the time it currently takes. With that improvement it is projected that nearly double the number of people can be rescued as before.
AFWERX is an arm of the United States Air Force that supports aircraft technology development for commercial and military purposes. VSDDL and ACE Lab are part of the Department of Aerospace Engineering at Auburn University in Auburn, Alabama.
ABOUT TRANSCEND AIR CORPORATION
Transcend Air has designed a family of high speed tiltwing VTOL aircraft. Its Vy 400 is three times faster than helicopters with half the operating costs. Expectations are that the Vy 400 will dominate the VIP transport helicopter segment. It will also enable a new city-center to city-center Aerial Regional Transport service that is up to five times faster door to door, and lower cost as compared with current air travel options. Since 2009, Transcend Air has built and flown 15 prototype VTOL aircraft, giving their patented Vy a long lineage of real-world experience. The Vy 400 will not require new regulatory regimes or air traffic control systems because it utilizes proven technologies that include the General Electric CT7-8 engine and BRS Aerospace whole-aircraft parachute. The Vy 400 brings with it the promise of civil VTOL flight that is within everyone’s reach.
For additional information see www.Transcend.aero
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005201/en/
Contact information
Peter Schmidt, peter@transcend.aero
t. 781-883-4818
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release
Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
